Transcriptomics

Dataset Information

0

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells leading to enhanced adoptive cell therapy


ABSTRACT: The manipulation of T cell metabolism to enhance anti-tumor activity is an area of active investigation. Here, we report that activating the amino acid starvation response in effector CD8+ T cells ex vivo using the General Control Non-depressible 2 (GCN2) agonist halofuginone (halo) enhances oxidative metabolism and effector function. Further characterization revealed that halo-treated CD8+ T cells increased expression of the large neutral amino acid (LNAA) transporter CD98 as well as the co-stimulatory marker 4-1BB. Mechanistically, we identified autophagy coupled with the CD98-mTOR axis as key downstream mediators of the phenotype induced by halo treatment. The adoptive transfer of halo-treated CD8+ T cells into mice bearing well-established tumors led to robust tumor control and curative responses. Halo-treated T cells also synergized in vivo with a 4-1BB agonistic antibody to control tumor growth in a mouse model resistant to immunotherapy. Importantly, treatment of human CD8+ T cells with halo resulted in similar metabolic and functional reprogramming. These findings demonstrate that activating the amino acid starvation response with the GCN2 agonist halofuginone can enhance T cell metabolism, effector function and anti-tumor activity, with the potential to augment existing clinical immunotherapeutic approaches.

ORGANISM(S): Mus musculus

PROVIDER: GSE255244 | GEO | 2024/02/17

REPOSITORIES: GEO

Similar Datasets

2014-05-29 | E-GEOD-47478 | biostudies-arrayexpress
2009-04-19 | E-GEOD-15624 | biostudies-arrayexpress
2009-04-10 | GSE15624 | GEO
2014-05-29 | GSE47478 | GEO
2023-05-08 | GSE220169 | GEO
2010-08-01 | E-GEOD-22452 | biostudies-arrayexpress
2021-05-26 | GSE156850 | GEO
2022-12-01 | GSE188460 | GEO
2020-03-22 | GSE145203 | GEO
2007-10-08 | E-GEOD-2275 | biostudies-arrayexpress